Results 81 to 90 of about 7,683 (166)

Molecular characterization of rifabutin-resistance in refractory Helicobacter pylori infection in Taiwan

International Journal of Infectious Diseases
Objectives: To explore the molecular characteristics of rpoB, encoding β-subunit of DNA-directed RNA polymerase, and unravel the link to rifabutin-resistance in patients with refractory Helicobacter pylori infection. Methods: From January 2018-March 2021,
Chia-Jung Kuo, Ngoc-Niem Bui, Jun-Nong Ke, Cheng-Yu Lin, Wey-Ran Lin, Ming-Ling Chang, Hui-Yu Wu, Mei-Zi Huang, Cheng-Hsun Chiu, Cheng-Tang Chiu, Chih-Ho Lai   +10 more
doaj   +1 more source

Rifabutin as salvage therapy for Helicobacter pylori eradication: Cornerstones and novelties

, 2022
When several Helicobacter pylori eradication treatments fail, guidelines recommend a cultured guided approach; however, culture is not widely available. Therefore, a rifabutin based regimen could be the best solution. Rifabutin indeed shows a low rate of
Rendina M., Ierardi E., Di Leo A., Celiberto F., Pricci M., Losurdo G., Girardi B., Iannone A., Borraccino A. V.   +8 more
core   +1 more source

Rifabutin disk diffusion on chelated Mueller-Hinton agar: a robust methodological framework for accurate Acinetobacter baumannii susceptibility testing

Journal of Clinical Microbiology
Carbapenem-resistant Acinetobacter baumannii (CRAB) is an extensively drug-resistant pathogen requiring new therapeutic strategies. Rifabutin (RBT), a U.S.
Michelle Zorawik, Jordyn VanOrman, Luke Bender, Lauren Tanner, Rosemary She, Brad Spellberg, Brian Luna   +6 more
doaj   +1 more source

Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis

, 2009
Human immunodeficiency virus (HIV)-associated tuberculosis is difficult to treat, given the propensity for drug interactions between the rifamycins and the antiretroviral drugs.
Symes, Stephen, Ashkin, David, Graham, Jenny J, Hollender, Elena, Maasen, Diane, Espinoza, Luis A, Rivero, Rafael O, Farrell, Karen, Stambaugh, Jerry Jean, Peloquin, Charles A, Boulanger, Catherine, Karen Farrell, Jenny J. Graham, Luis A. Espinoza, Elena Hollender, Rafael O. Rivero, David Ashkin, Stephen Symes, Catherine Boulanger, Charles A. Peloquin, Jerry Jean Stambaugh, Diane Maasen   +21 more
core   +1 more source

A drug interaction study investigating the effect of Rifabutin on the pharmacokinetics of Maraviroc in healthy subjects - Fig 3

, 2019
Steady-state geometric mean Maraviroc concentration-time profile (log-scale) for subjects receiving Maraviroc alone (squares and solid line) and Maraviroc plus Rifabutin (circles and dashed line)(A). Steady-state maraviroc concentration-time profile (log-
E. Sabri (7542692), C. la Porte (7542683), G. Zhang (808141), M. Ghannad (7542677), R. Mallick (5874875), M. Dennehy (7542680), S. Kanji (3407216), D. W. Cameron (7542695), I. Seguin (7542686), D. Tardiff (7542689)   +9 more
core   +1 more source

Population pharmacokinetic drug–drug interaction pooled analysis of existing data for rifabutin and HIV PIs [PDF]

, 2016
Extensive but fragmented data from existing studies were used to describe the drug-drug interaction between rifabutin and HIV PIs and predict doses achieving recommended therapeutic exposure for rifabutin in patients with HIV-associated TB, with ...
McIlleron, Helen, Svensson, E.M., Niebecker, Ronald, Vis, Peter, Flexner, C., Olliaro, Piero L, Hennig, Stefanie,, Weiner, Marc H, Fourie, P.B., Peloquin, Charles A, Olliaro, P.L., Pym, Alex, Karlsson, M.O., Flexner, Charles, Peloquin, C.A., Gallicano, K., Weiner, M.H., Pym, A., Olliaro, Piero L., Peloquin, Charles A., Bonora, S., Hennig, S., Fourie, P Bernard, Hennig, Stefanie, Fourie, P. Bernard, McIlleron, H., Niebecker, R., Karlsson, Mats O,, Bonora, Stefano, Weiner, Marc H., Gallicano, Keith, Svensson, Elin M., Borona, Stefano, Niebecker, Ronald,, Svensson, Elin M,, Karlsson, Mats O., Vis, P., Fourie, Petrus Bernardus   +37 more
core   +1 more source

Abstract Supplement HIV Glasgow 8–11 November 2026, Glasgow, UK/Virtual

Journal of the International AIDS Society, Volume 29, Issue S6, November 2026.
wiley   +1 more source

Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact?

, 2013
It has long been assumed that some rifampicin-resistant Mycobacterium tuberculosis strains are susceptible to, and thus treatable with, rifabutin.
Jureen, P., Angeby, K,, P. Jureen, C. G. Giske, Giske, C G.,, Chryssanthou, E,, Hoffner, S,, Hoffner, S., K. Angeby, T. Schon, Kahlmeter, Gunnar,, Angeby, K., Giske, C. G., Schon, Thomas,, Jureen, P,, Kahlmeter, G,, S. Hoffner, Chryssanthou, E., E. Chryssanthou, G. Kahlmeter, Schon, T., Giske, CG, Jureen, P, Angeby, K, Kahlmeter, G, Schon, T   +25 more
core   +1 more source

Rifabutin based triple therapy for eradication of H.pylori primary and secondary resistant to tinidazole and clarithromycin

, 2005
Background. Rifabutin has been empirically used in Helicobacter pylori infections resistant to triple therapy. There are no data on primary and secondary resistance to rifabutin and its use in specific cases. Aim.
TORACCHIO, Sonia, MARZIO, Leonardo, CELLINI, Luigina, DI BARTOLOMEO S., CAPODICASA S.   +4 more
core  

Rifamycin SV and its derivative, rifabutin, bind directly to the BCL6-POZ domain.

, 2014
Schematic diagram to compare the structures of (A) rifamycin SV and (C) rifabutin. These two compounds differ with respect to the side chains on C-3 and C-4. (B) and (D) TROSY 1H,15N HSQC spectra of 280 μM BCL6-POZ domain.
John W. R. Schwabe (530387), Simon D. Wagner (530388), Louise Fairall (530385), Robert Ford (89276), Sian E. Evans (530384), Paul Ko Ferrigno (41085), Andrew G. Jamieson (530386), Benjamin T. Goult (173495)   +7 more
core   +1 more source